entertainment -WSS

entertainment

author：comprehensive 2025-09-28 23:45:01 - browse：51341

Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Why palliative psychiatry is worth discussing

WSS

6 solutions to address cancer drug shortages and others

Flu, Covid vaccination rates decline, new survey data show

Alabama frozen embryo ruling has major implications for IVF clinics

Experts study whether long Covid risk adds up with each reinfection

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

entertainment

entertainment

Wikipedia

Cancer drug shortages should be causing more outrage

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Apple is now the first public company to be valued at $3 trillion

The United States is paying nearly triple for new Covid vaccines

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Alabama frozen embryo ruling has major implications for IVF clinics

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

hotspot

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

NIH study of ME/CFS points to clear biological hallmarks

Medicare innovation center doesn’t save money, experts say

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

WHO recommends second malaria vaccine

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

explore

explore

explore

Wikipedia